# Efficacy analysis of quadruple nerve decompression surgery for lower limb diabetic peripheral neuropathy

**Authors:** Yong Zhang, Zonghan Li, Tianyi Ma, Xiaodong Xu, Jicheng Li, Rufei Dai, Jiawei Shen

PMC · DOI: 10.3389/fsurg.2025.1702779 · Frontiers in Surgery · 2026-02-05

## TL;DR

Quadruple nerve decompression surgery significantly reduces pain and improves nerve function in patients with diabetic peripheral neuropathy.

## Contribution

This study demonstrates sustained efficacy of quadruple nerve decompression for refractory diabetic neuropathy over a 30-month period.

## Key findings

- 93.3% of patients achieved at least 50% pain relief after surgery.
- Two-point discrimination improved significantly, with 68.9% returning to normal levels.
- Nerve conduction velocity improved in 64.4% to 75.6% of nerves.

## Abstract

To explore the efficacy of quadruple nerve decompression in treating painful diabetic peripheral neuropathy (PDPN) of lower extremity, and to evaluate its clinical value in pain relief and sensory recovery.

A retrospective analysis was performed on 26 PDPN patients (45 sides), all of whom underwent quadruple nerve decompression, including release of the common peroneal nerve (CPN), superficial peroneal nerve (SPN), deep peroneal nerve (DPN), and tibial nerve (TN). Changes in the Visual Analog Scale (VAS) score, two-point discrimination (TPD), sensory nerve conduction velocity (SCV), and Toronto Clinical Scoring System (TCSS) score were evaluated by comparing preoperative values with those at an average of 30.46 months postoperatively. Statistical analysis was conducted using the paired t-test.

Postoperative VAS scores were significantly reduced, from 7.31 ± 1.62 to 2.51 ± 1.47 (P < 0.001), with 93.3% of limbs achieving at least 50% pain relief. TPD showed significant improvement, decreasing from 13.80 ± 3.01 mm to 7.49 ± 2.07 mm (P < 0.001), and 68.9% of patients returned to normal levels. The proportion of nerves showing an SCV improvement of ≥5 m/s ranged from 64.4% to 75.6%. TCSS scores shifted from all being grade III before surgery to mild or moderate in 93.3% of cases. No severe complications were observed postoperatively.

Significant pain relief and improvement in sensation and nerve function have been achieved in patients with PDPN through quadruple nerve decompression, which addresses multiple potential nerve entrapment sites. This procedure, building upon existing evidence, demonstrates sustained efficacy in pain relief and sensory recovery over a median 30-month follow-up, offering a refined surgical option for patients with refractory PDPN who have failed conservative management.

## Full-text entities

- **Genes:** CLEC3B (C-type lectin domain family 3 member B) [NCBI Gene 7123] {aka MCDR4, TN, TNA}
- **Diseases:** postoperative infection (MESH:D013530), diabetic lower-extremity peripheral neuropathy (MESH:D010523), sensory loss (MESH:C580162), axonal degeneration (MESH:D009410), deformity (MESH:D009140), heart failure (MESH:D006333), neuropathy (MESH:D009422), restricted movement (MESH:D002313), extensor (MESH:D009127), demyelination (MESH:D003711), adhesions (MESH:D000267), TPD (MESH:D010468), nerve ischemia (MESH:D018917), loss of sensation (MESH:D006987), multiple-nerve involvement (MESH:C564676), ACS (MESH:D000168), transection injury (MESH:D061220), effusion (MESH:D000080324), intraneural oedema (MESH:C536897), PDPN (MESH:D003929), hypoglycemia (MESH:D007003), Infection (MESH:D007239), Coagulation abnormalities (MESH:D001778), weight gain (MESH:D015430), impaired pain and temperature (MESH:C565868), ischaemia (MESH:D007511), stenosis (MESH:D003251), metabolic damage (MESH:D008659), CPN (MESH:D020427), Pain (MESH:D010146), nerve compression (MESH:D009408), muscle atrophy (MESH:D009133), TN (MESH:D020429), metabolic disturbance (MESH:D024821), hyperglycemia (MESH:D006943), edema (MESH:D004487), atrophy (MESH:D001284), decline in nerve function (MESH:D060825), hepatorenal failure (MESH:D051437), DPN (MESH:C536001), sensory disturbance (MESH:D012678), Diabetes (MESH:D003920), microangiopathy (MESH:D014652), polyneuropathy (MESH:D011115), muscle weakness (MESH:D018908), postoperative pain (MESH:D010149), neuropathic symptoms (MESH:D001750)
- **Chemicals:** capsaicin (MESH:D002211), DPN (-), AGE (MESH:D017127), blood glucose (MESH:D001786)
- **Species:** Bos taurus (bovine, species) [taxon 9913], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12951633/full.md

## Figures

10 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12951633/full.md

## References

32 references — full list in the complete paper: https://tomesphere.com/paper/PMC12951633/full.md

---
Source: https://tomesphere.com/paper/PMC12951633